Balchem Corporation

What they do

Balchem develops, manufactures, and markets specialty performance ingredients for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Its three reportable segments are Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. Products include choline nutrients, mineral amino acid chelates, vitamin K2, MSM, microencapsulation solutions, and choline chloride for feed.

Revenue drivers

• Human Nutrition and Health — Largest segment; 2025 net sales $659.4M (64% of total), up 9.9% year-over-year. Sells human-grade choline, mineral chelates, vitamin K2, MSM, and food/beverage ingredients. In Q2 2026, record sales of $176.9M, up 10%.
• Animal Nutrition and Health — 2025 net sales $230.9M (22% of total), up 7.5% year-over-year. Products include microencapsulated supplements and choline chloride for poultry, pet, and swine. Q2 2026 also showed sales and earnings growth.
• Specialty Products — 2025 net sales $141.0M (14% of total), up 6.2% year-over-year. Includes performance gases, plant nutrition, sterilization, and fumigation products. Q2 2026 posted excellent sales and earnings growth.

Recent performance

In fiscal 2025, net sales rose 8.8% to $1.037B, operating earnings rose 14.4% to $209.3M, and net earnings rose 20.5% to $154.8M. Q2 2026 (June 30, 2026) net sales increased 11.2% to $284.0M versus the prior-year quarter; net earnings rose 16.6% to $44.6M; adjusted EBITDA rose 12.6% to $77.9M; diluted EPS was $1.39 (up from $1.17). For H1 2026, net sales were $554.7M (up 9.6%) and net earnings were $84.9M (up 12.7%).

Strategy

Balchem invests in scientific data, intellectual property, and brand value to differentiate from lower-cost competitors. It partners with customers from ideation to commercialization, leveraging capabilities in spray drying, extrusion, and agglomeration. The company also focuses on sustainability, integrated into governance and operations. Recent actions include expanding the credit facility to $650M and repurchasing $114M of stock over the trailing twelve months to balance growth, innovation, and acquisitions.

Risks

• Overseas operations and trade policy — Sales and manufacturing outside the U.S. face risks from tariffs, sanctions, trade restrictions, political instability, and currency fluctuations.
• Raw material and supply chain — Shortages or price increases in raw materials, and supply chain disruptions from geopolitical conflicts, could hurt margins and operations.
• Regulatory/ethylene oxide — Regulatory requirements for ethylene oxide users have impacted and may continue to impact sterilization of medical devices, affecting a niche business.
• Competition and brand value — Growth in human nutrition relies on differentiation from lower-cost competitors; if brand value erodes, sales could suffer.

Outlook

Management remains optimistic, citing strong growth momentum across all three segments and 'excellent first half of 2026 results.' The expansion of the credit facility to $650 million and the share repurchase program indicate intent to fund future growth, innovation, and acquisitions. No specific numeric guidance is provided in the excerpts.